Guest: Charles Turck, PharmD, BCPS, BCCCP

With the growing amount of illicit pharmaceutical drugs and medical supplies filling the global market amid the COVID-19 pandemic, are we at risk of facing another public health crisis? Listen in as Dr. Charles Turck brings this troubling trend to light.

Published June 3, 2020

Host: Matt Birnholz, MD

Guest: Frank Scott, MD

Disease and drug monitoring can help us improve our approach to managing our patients’ IBD, but when’s the right time to perform that practice and how do we go about it? Joining Dr. Matt Birnholz at the third annual Crohn’s & Colitis Congress in Austin, Texas to answer those questions and more was Dr. Frank Scott, Assistant Professor of Medicine from the Crohn’s & Colitis Center at the University of Colorado.

Host: Linda Bernstein, Pharm.D.

The Drug Enforcement Administration (DEA) issued a new guidance for the issuance of oral Schedule II prescriptions in light of the COVID-19 pandemic and nationwide public health emergency. Pharmacist Dr. Linda Bernstein details the DEA’s temporary exceptions to the regulations to ease prescribing and dispensing of these controlled substances during this challenging time.

Published April 24, 2020

Host: John Russell, MD

In the absence of FDA-approved therapies and vaccines to battle the COVID-19 pandemic, healthcare professionals on the frontlines are turning to malarial medicines like chloroquine and hydroquinone to treat their patients—despite the fact that there’s no evidence to support their use. But this isn’t the first time that medicines have been used for a different purpose than what they were intended for, as Dr. John Russell explains.

Published April 21, 2020

Host: Linda Bernstein, Pharm.D.

The Centers for Disease Control provided a guidance for pharmacy staff to minimize their risk of exposure to the COVID-19 virus and reduce customer risk during the pandemic. Pharmacist Dr. Linda Bernstein presents highlights of the guidance that offers recommendations on ways to minimize viral exposure when medication dispensing along with methods to minimize patient-to-patient contact.

Published on April 17, 2020

Host: Linda Bernstein, Pharm.D.

The Food and Drug Administration has issued a guidance on its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements during the COVID-19 pandemic that include laboratory monitoring and imaging studies. Pharmacist Dr. Linda Bernstein discusses the guidance and its impact on patient access to certain REMS drugs when patients self-isolate or are subject to quarantine due to COVID-19.

Published April 17, 2020

Host: Linda Bernstein, Pharm.D.

The American Society of Health Systems Pharmacists (ASHP) recently published recommendations for prescribers, pharmacists and patients when considering the proper use of experimental treatments during the COVID-19 pandemic. Inappropriate prescribing of experimental treatments “just in case” or for patients not at high risk of severe illness may lead to insufficient supplies of critical medicines that are needed to treat other patients who depend on these medicines.

Linda Bernstein, Pharm.D., reports on this important guidance designed to limit drug shortages and the worsening of existing shortages that can occur when practitioners and patients stock up and hoard their medication supplies.

Published April X, 2020

Host: Linda Bernstein, Pharm.D.

The World Health Organization (WHO) and partners recently announced it was launching an international clinical trial with the goal of generating significant worldwide data from thousands of patients to find the most effective treatments for COVID-19. Pharmacist Dr. Linda Bernstein brings you an update on the WHO SOLIDARITY trial, which will offer clinicians simplified procedures to enable even overloaded hospitals to participate.

Published April 17, 2020

Host: Joshua Sharfstein, MD

Guest: Howard Sklamberg

What does a global pandemic mean for the world’s drug supply chain? Howard Sklamberg, lawyer and former FDA deputy commissioner, talks to Dr. Josh Sharfstein about the threats that COVID-19 poses to medications for everything from cancer to diabetes to hypertension.

Published April 3, 2020

Host: Linda Bernstein, Pharm.D.

This special episode of The Drug Report provides an update regarding the antiviral Remdesivir, which is the first investigational therapeutic to be studied under an FDA-approved NIH adaptive randomized controlled clinical trial for hospitalized COVID-19 patients. Currently, there are three options through clinical trials for obtaining remdesivir for the treatment of hospitalized patients with COVID-19 and pneumonia in the United States, as pharmacist Dr. Linda Bernstein explains.

Published April 10, 2020